Myriad Genetics MYGN
-
Myriad Genetics' Wild Ride: False Assumptions Whipsaw Stock
… By Joshua Anderson : If you're a stockholder of Myriad Genetics ( MYGN ) you're probably feeling a little queasy right ..... ruling in Association for Molecular Pathology v. Myriad Genetics Inc. was exactly what most observers and analysts …
-
Myriad Genetics ([[ MYGN ]] -7.1%) slumps and is now off ~22% since intraday highs hit Thursday after the Supreme Court's ruling on gene patents. Investors' fears that methods outside of MYGN's cDNA ...
Myriad Genetics ( MYGN -7.1% ) slumps and is now off ~22% since intraday highs hit Thursday ..... s ruling on gene patents . Investors' fears that methods outside of MYGN 's cDNA synthetics can be used to analyze genes were seemingly confirmed …
-
Shares of Myriad Genetics ([[ MYGN ]] -5.6%) did an abrupt about-face late in the day, finishing lower after hovering solidly in the green for most of the day. A couple reasons for the slide: Leerink ...
Shares of Myriad Genetics ( MYGN -5.6% ) did an abrupt about-face late in the day, finishing lower after hovering solidly in the green for most of the day …
-
Today's Supreme Court ruling did indeed deal a blow to Myriad's ([[ MYGN ]] +7.8%) claim to have right to be the sole user of the BRCA1 and BRCA2 genes, mutations in which show a high risk for breast ...
… did indeed deal a blow to Myriad's ( MYGN +7.8% ) claim to have right to be the ..... not to rule on any applications of what MYGN had learned about the two cancer-suggesting ..... Nor did it limit any right to a patent on MYGN 's methods for manipulating the genes …
-
The Supreme Court's ruling on Myriad Genetics ([[ MYGN ]] +10.4%) today is another shot across the bow of the U.S. Patent Trademark Office. The court in recent years has sought to constrict the scope ...
The Supreme Court's ruling on Myriad Genetics ( MYGN +10.4% ) today is another shot across the bow of the U.S. Patent Trademark Office. The court in recent years has sought …
-
More on Myriad Genetics ([[ MYGN ]] +8.9%): The mixed ruling was not a surprise to many, as the Court expressed skepticism over whether human DNA extracted from the body could be patented like a ...
More on Myriad Genetics ( MYGN +8.9% ): The mixed ruling was not a surprise to many, as the Court expressed skepticism over whether human DNA extracted …
-
U.S. top court says extracted human DNA cannot be patented
WASHINGTON, June 13 (Reuters) - The U.S. Supreme Court on Thursday issued a mixed ruling in a case concerning patents held by Myriad Genetics Inc over the closely watched issue of whether human genes can be patented.
-
Shares of Myriad Genetics ([[ MYGN ]] +7.8%) resume trading following a brief halt on news that its gene patents are said to have been limited by the Supreme court ruling.
Shares of Myriad Genetics ( MYGN +7.8% ) resume trading following a brief halt on news that its gene patents are said to have been limited by the Supreme court ruling. Post your comment!
-
U.S. Supreme Court Gives Myriad Genetics a Partial Victory; No Change to Our Fair Value Estimate
… not be patented but that complementary DNA is eligible, awarding a partial, yet largely expected, victory to Myriad Genetics MYGN . Overall, we consider the ruling incrementally positive but ultimately of limited impact to Myriad over the long …
-
As The Patent Cliff Approaches, Buy TrovaGene
By Logical Assessment : Alarming Shifts in Healthcare I'm not James Altucher , but I do believe in investing in companies that stand to benefit from "long-term demographic trends." These long-term demographic trends tend to be very transparent for the healthcare sector. The IMS Institute for Health